Supplemental Figure 5

Aug 15, 2014

10 likes | 110 Views

Supplemental Figure 5. A. MTLn3 GFP-CXCL12. MTLn3 GFP-pQCXIP. C. B. ***. CXCR4. IgG. % of max. BMM Chemotaxis to CXCL12. % of max. CXCR4-PE. CXCR4-PE. IgG. CXCR4. B.

Share Presentation

Embed Code

Link

mtln3 gfp
cxcr4-pe cxcr4-pe igg cxcr4
figure
bmm chemotaxis
pqcxip c

thora

Download Presentation

Supplemental Figure 5

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Supplemental Figure 5 A. MTLn3 GFP-CXCL12 MTLn3 GFP-pQCXIP C. B. *** CXCR4 IgG % of max BMM Chemotaxis to CXCL12 % of max CXCR4-PE CXCR4-PE IgG CXCR4 B.

Supplemental Figure 1

Supplemental Figure 1. Fig. S1 qRT -PCR analysis of the genes flanking the sbp2’ / sbp2’’ knockouts. All values are given relative to the abundance of transcript observed in P1/7. Data presents the mean from 3 biological replicates. .

91 views • 1 slides

Supplemental Figure 3

Supplemental Figure 3. Purified Collagens. A). B). Purified Collagen1 ( μ g). 0.12. 0.25. 0.5. 1. 2.5. 5. 10. 20. Purified Col1. Purified Col3. Col1. Purified Collagen3 ( μ g). Col1. 0.12. 0.25. 0.5. 1. 2.5. 5. 10. 20. Col3. Col3. Col1. Col3. Arbitrary Units.

111 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. d-ROM (Carr U). P = 0.0512. recurrence-free period (day). Correlation between d-ROM levels and recurrence-free period in 36 multicentric occurrence cases using linear regression analysis.

72 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1.

62 views • 1 slides

Supplemental Figure 3

Supplemental Figure 3. Time course of mean arterial pressure, albuminuria, and kidney injury after reduction in renal mass and treatment of C57BL/6 mice with deoxycorticosterone acetate + saline drinking water (DOCA) or treatment of CD-1 mice with hydralazine.

123 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. A. P-VEGFR2. Tubulin. PlGF-1 250 ng/mL - + + + + Time (min) - 5 10 15 30. B. P-VEGFR2. Tubulin. C.

78 views • 3 slides

Supplemental Figure 2

MK-1775. MK-1775 + 37.5 nM MK-8776. MK-1775 + 75 nM MK-8776. MK-1775 + 150 nM MK-8776. MK-1775 + 300 nM MK-8776. Supplemental Figure 2. A. B. HRE cells. fractional proliferation. MK-8776 ( μ M). MK-1775 ( μ M).

100 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. SPERM A -. Sp_D62[A-]. Sp_D62[A+]. SPERM A +. Sp_D62[Tt]. SPERM TOTAL. Sp_D64[Tt]. Sp_D66[Tt]. Sp_P1[Tt]. Sp_D62[SP]. SPERM SPIA. Sp_D64[SP]. Sp_D66[SP]. Sp_P2[SP]. Te_PCl[SP]. TESTES SPIA. Te_PAm[A+]. TESTES Poly (A + ). Te_PCl[A+]. PRM2.

170 views • 6 slides

Supplemental Figure S1

Supplemental Figure S1. A. MDA-MB-231 BCL-2. MCF-7 BCL-2. MDA-MB-231. MCF-7. Bcl-2. Bcl-2. Actin. Actin. B. Supplemental Figure S2. **. *. *. *. *. Control. - - - - - - -. Cisplatin 30 M.

115 views • 6 slides

Supplemental Figure 2

Supplemental Figure 2. Supplemental Figure 2. Combined use of crizotinib or TAS-115 with erlotinib reverses resistance to EGFR-TKI induced by exogenous HGF on HCC827 cell.

153 views • 1 slides

Supplemental Figure 5

Trastuzumab-treated. Control-treated. A. MDA-MB-453. 14.2%. 10.7%. DEAB-inhibited. DEAB-inhibited. B. JIMT-1. 5.2%. 5.4%. DEAB-inhibited. DEAB-inhibited. C. Sum159-HER2. 7.1%. 36%. DEAB-inhibited. DEAB-inhibited. Trastuzumab-treated. Control-treated. D. Supplemental Figure 5.

123 views • 1 slides

Supplemental Figure 2

si RNA #1. si RNA #1. si RNA #1. si RNA #1. si RNA #2. si RNA #2. si RNA #2. si RNA #2. si RNA #3. si RNA #3. si RNA #3. si RNA #3. si control. si control. si control. si control. Casp-9. Casp-2. 47kDa. 51kDa. b -actin. b -actin. Relative mRNA expression. RAIDD. PIDD.

120 views • 1 slides

Supplemental Figure 1

Supplemental Figure 1. True leaf from 2 nd to 7 th nodes. (a). M. 1 st (IN) IN. 2 nd. 3 rd. 4 th. 5 th. 6 th. 7 th. PC. ALSV-RNA2. 7. PsEF1- a. 6. 1. 2. 3. 5. True leaf from 2 nd to 7 th nodes. ALSV inoculation. 4. 2 nd. 3 rd. 4 th. 5 th. 6 th. 7 th. 3. Mock. 2.

90 views • 3 slides

Supplemental Figure.

Supplemental Figure. Legend:

82 views • 3 slides

Supplemental Figure 5

Supplemental Figure 5.

61 views • 1 slides

Supplemental Figure 5

Supplemental Figure 5. p <0.05. p =0.05. a. b. p <0.05. p <0.05. p <0.05. p <0.05. c. Muscle. d. Liver. + - + - UCP3. p <0.01. UCP3. SDH. p <0.05.

74 views • 1 slides

Vernin et al., supplemental Figure 5

PI positive cells (%). Vernin et al., supplemental Figure 5.

97 views • 1 slides

Supplemental Figure S 5

A. B. Supplemental Figure S 5.

66 views • 1 slides

Supplemental Figure 3

Supplemental Figure 3.

59 views • 1 slides

Figure I supplemental

Figure I supplemental.

159 views • 6 slides

Supplemental Figure 2

Supplemental Figure 2. a. ADP titration (Clark-type electrode). ~10.00. ~10.27. ~7.01. ~5.11. ~5.00. ~4.03. ADP titration (Seahorse XF24). b. ~3.89. ~3.10. ~2.62. ~2.03. ~1.63. c. Mitochondrial integrity test (Clark-type electrode). d.

97 views • 2 slides

Supplemental Figure 2

Supplemental Figure 2. A. B. C. D. E. F. H. G. I. K. L. J.

91 views • 1 slides

More Related